Sagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne Treatment

Dow Jones

Jun 04, 2025

By Connor Hart

Shares of Sagimet Biosciences rose after the company disclosed what it called positive results from a recent clinical trial of its treatment for moderate-to-severe acne.

The stock jumped 42%, to $5.20, in pre-market trading Wednesday. Through Tuesday's close, shares have lost more than one-fifth of their value in the past year.

The biopharmaceutical company before the bell said that its acne treatment, denifanstat, met all primary and secondary endpoints in a Phase 3 clinical trial in China.

Denifanstat was generally well-tolerated by patients during the trial, with incidence rates of treatment-emergent adverse events comparable between the treatment and placebo, the company said.

Chief Executive David Happel called the trial results highly encouraging, noting that the treatment represents a potentially novel approach to treat acne, one of the most prevalent skin diseases that physicians address annually.

Sagimet additionally said it recently initiated a Phase 1 first-in-human clinical trial for a separate therapy, TVB-3567, which is planned to be developed to treat acne in the U.S.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

June 04, 2025 06:44 ET (10:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2540057224"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540057224\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540057224?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540057224","market":"other","top_or_hot":-1,"title":"Sagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Sagimet Biosciences rose after the company disclosed what it called positive results from a recent clinical trial of its treatment for moderate-to-severe acne. \n</p>\n<p>\n  The stock jumped 42%, to $5.20, in pre-market trading Wednesday. Through Tuesday's close, shares have lost more than one-fifth of their value in the past year. \n</p>\n<p>\n  The biopharmaceutical company before the bell said that its acne treatment, denifanstat, met all primary and secondary endpoints in a Phase 3 clinical trial in China. \n</p>\n<p>\n  Denifanstat was generally well-tolerated by patients during the trial, with incidence rates of treatment-emergent adverse events comparable between the treatment and placebo, the company said. \n</p>\n<p>\n  Chief Executive David Happel called the trial results highly encouraging, noting that the treatment represents a potentially novel approach to treat acne, one of the most prevalent skin diseases that physicians address annually. \n</p>\n<p>\n  Sagimet additionally said it recently initiated a Phase 1 first-in-human clinical trial for a separate therapy, TVB-3567, which is planned to be developed to treat acne in the U.S. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 04, 2025 06:44 ET (10:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-04 18:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Sagimet Biosciences rose after the company disclosed what it called positive results from a recent clinical trial of its treatment for moderate-to-severe acne. \n</p>\n<p>\n  The stock jumped 42%, to $5.20, in pre-market trading Wednesday. Through Tuesday's close, shares have lost more than one-fifth of their value in the past year. \n</p>\n<p>\n  The biopharmaceutical company before the bell said that its acne treatment, denifanstat, met all primary and secondary endpoints in a Phase 3 clinical trial in China. \n</p>\n<p>\n  Denifanstat was generally well-tolerated by patients during the trial, with incidence rates of treatment-emergent adverse events comparable between the treatment and placebo, the company said. \n</p>\n<p>\n  Chief Executive David Happel called the trial results highly encouraging, noting that the treatment represents a potentially novel approach to treat acne, one of the most prevalent skin diseases that physicians address annually. \n</p>\n<p>\n  Sagimet additionally said it recently initiated a Phase 1 first-in-human clinical trial for a separate therapy, TVB-3567, which is planned to be developed to treat acne in the U.S. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 04, 2025 06:44 ET (10:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1145","symbol_name":"广播","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2540057224","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540057224","pubTimestamp":1749033840,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Sagimet Biosciences rose after the company disclosed what it called positive results from a recent clinical trial of its treatment for moderate-to-severe acne.The stock jumped 42%, to $5.20, in pre-market trading Wednesday. Through Tuesday's close, shares have lost more than one-fifth of their value in the past year.The biopharmaceutical company before the bell said that its acne treatment, denifanstat, met all primary and secondary endpoints in a Phase 3 clinical trial in China.Denifanstat was generally well-tolerated by patients during the trial, with incidence rates of treatment-emergent adverse events comparable between the treatment and placebo, the company said.Chief Executive David Happel called the trial results highly encouraging, noting that the treatment represents a potentially novel approach to treat acne, one of the most prevalent skin diseases that physicians address annually.Sagimet additionally said it recently initiated a Phase 1 first-in-human clinical tria","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1145":"广播","SGMT":"Sagimet Biosciences Inc.","00511":"电视广播","BK4139":"生物科技"},"translate_title":"Sagimet Biosciences股价因痤疮治疗临床试验结果积极而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00511":0.62,"SGMT":1},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Sagimet Biosciences rose after the company disclosed what it called positive results from a recent clinical trial of its treatment for moderate-to-severe acne. \n\n\n  The stock jumped 42%, to $5.20, in pre-market trading Wednesday. Through Tuesday's close, shares have lost more than one-fifth of their value in the past year. \n\n\n  The biopharmaceutical company before the bell said that its acne treatment, denifanstat, met all primary and secondary endpoints in a Phase 3 clinical trial in China. \n\n\n  Denifanstat was generally well-tolerated by patients during the trial, with incidence rates of treatment-emergent adverse events comparable between the treatment and placebo, the company said. \n\n\n  Chief Executive David Happel called the trial results highly encouraging, noting that the treatment represents a potentially novel approach to treat acne, one of the most prevalent skin diseases that physicians address annually. \n\n\n  Sagimet additionally said it recently initiated a Phase 1 first-in-human clinical trial for a separate therapy, TVB-3567, which is planned to be developed to treat acne in the U.S. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 04, 2025 06:44 ET (10:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}